Google
ENGN — ENGENE HOLDINGS INC. COMMON STOCK (Healthcare >> Biotechnology)
ENGN FAQ
What is ENGN's ROE?
ENGENE HOLDINGS INC. COMMON STOCK reports a Return on Equity (ROE) of -43.49%.
What is ENGN's dividend yield?
ENGENE HOLDINGS INC. COMMON STOCK offers a dividend yield of 0.00%.
What is ENGN's Deepscope Quality Score?
Deepscope rates ENGN's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ENGN?
Deepscope's AI Timing Score for ENGN is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ENGN belong to?
ENGENE HOLDINGS INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.64
Price
-0.08
(-4.65%)
Day Change
|
|
|---|
ENGN, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.64 |
| PBV / Sector |
0.39 / 4.63
GREAT
|
| Earning Per Share | -1.83 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
4.54 M
GREAT
|
| Average 1W Daily Value |
1.48 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-06 09:09:23 |
| Symbol | ENGN |
| Name | ENGENE HOLDINGS INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 66.99 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 109.86 / 8,857.28 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4868 Rue Levy, Montreal, QC, Canada, H4R 2P1
Phone: 514 332 4888
Website: https://www.engene.com
Employees: 81
Sector: Healthcare >> Biotechnology
Description: enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
